Glover S, Borrego ME, Ray GM, & Roberts MH. (2022). Sodium-Glucose Cotransporter 2 Inhibitor Use Among Individuals Age <65 with Type 2 Diabetes and Heart Failure with Reduced Ejection Fraction: A Cost–Benefit Analysis. Dove Medical Press.
Chicago Style (17th ed.) CitationGlover S, Borrego ME, Ray GM, and Roberts MH. Sodium-Glucose Cotransporter 2 Inhibitor Use Among Individuals Age <65 with Type 2 Diabetes and Heart Failure with Reduced Ejection Fraction: A Cost–Benefit Analysis. Dove Medical Press, 2022.
MLA (9th ed.) CitationGlover S, et al. Sodium-Glucose Cotransporter 2 Inhibitor Use Among Individuals Age <65 with Type 2 Diabetes and Heart Failure with Reduced Ejection Fraction: A Cost–Benefit Analysis. Dove Medical Press, 2022.
Warning: These citations may not always be 100% accurate.